<p>丹佛，2025 年 12 月 23 日（GLOBE NEWSWIRE）-- SeaStar Medical Holding Corporation（納斯達克：ICU）是一家商業階段的醫療保健公司，專注於改變面臨器官衰竭和潛在生命危險的重症患者的治療，今天宣佈公司將進行 1 比 10 的反向股票拆分（Reverse Split），該拆分將於 2026 年 1 月 5 日東部時間凌晨 12:01 生效。公司的普通股將在 2026 年 1 月 5 日市場開盤時開始以拆分後調整的基礎在納斯達克資本市場（Nasdaq）交易。SeaStar Medical 的股票將繼續以 “ICU” 的股票代碼交易。</p>
<p>反向拆分的授權已於 2025 年 12 月 18 日在 SeaStar Medical 的 2025 年特別股東會議上獲得公司股東的批准。反向拆分的目的是提高公司普通股的市場價格，以便使公司重新符合納斯達克上市規則下的 1.00 美元最低出價價格要求。公司的普通股將以新的 CUSIP 號碼進行交易 – 81256L302。</p>
<p>由於反向拆分，每 10 股拆分前的普通股將自動合併並轉換為 1 股已發行和流通的普通股。記錄在冊的股東如果有權獲得部分股份，將收到一整股普通股以替代該部分股份。反向拆分減少了因行使或歸屬其未發行股票期權和某些認股權證而可發行的普通股數量，按反向拆分的比例調整，並導致這些股票期權和認股權證的行使價格按比例上升。</p>
<p>記錄在冊的股東將在反向股票拆分後收到來自公司的過户代理人——大陸股票轉讓和信託公司（Continental Stock Transfer and Trust Company）關於其股份所有權的信息。大陸股票轉讓和信託公司可通過 800-509-8856 聯繫。通過銀行、經紀人或其他代理持有股份的股東，其持倉將自動調整以反映反向拆分，無需在反向拆分中採取進一步行動，具體取決於經紀人的特定流程。</p>
<p>有關反向拆分的更多信息，請參閲 SeaStar Medical 於 2025 年 12 月 18 日向證券交易委員會提交的 8-K 表格當前報告。</p>
<p>關於 SeaStar Medical</p>
<p>SeaStar Medical 是一家商業階段的醫療保健公司，專注於改變面臨器官衰竭和潛在生命危險的重症患者的治療。QUELIMMUNE（SCD-PED）療法是 SeaStar Medical 基於其專利選擇性細胞治療設備（SCD）技術的首個商業產品。QUELIMMUNE（SCD-PED）療法於 2024 年獲得美國食品藥品監督管理局（FDA）的批准。它是 FDA 批准的唯一針對因膿毒症或膿毒症狀態導致的危及生命的急性腎損傷（AKI）在重症兒科患者中的超罕見病症的產品。SeaStar Medical 的選擇性細胞治療設備（SCD）療法已獲得 FDA 對六種治療適應症的突破性設備認定，使其在批准和商業推出時具有更快速的審批路徑和更有利的報銷動態。該公司目前正在進行針對需要持續腎臟替代治療（CRRT）的急性腎損傷（AKI）成年患者的 SCD 療法的 NEUTRALIZE-AKI 關鍵試驗，這是一種沒有有效治療方案的危及生命的疾病，每年影響美國超過 200,000 名成年人。</p>
<p>欲瞭解更多信息，請訪問 www.seastarmedical.com 或在 LinkedIn 或 X 上關注我們。</p>
<p>前瞻性聲明</p>
<p>本新聞稿包含根據 1955 年《私人證券訴訟改革法》“安全港” 條款的某些前瞻性聲明。這些前瞻性聲明包括但不限於，SeaStar Medical 對擬議的反向股票拆分的預期以及 SeaStar Medical 重新符合納斯達克上市規則的能力。諸如 “相信”、“項目”、“期望”、“預期”、“估計”、“打算”、“戰略”、“未來”、“機會”、“計劃”、“可能”、“應該”、“將”、“會”、“將會”、“將繼續”、“可能導致” 等類似表達旨在識別這些前瞻性聲明。前瞻性聲明是關於未來事件的預測、展望和其他聲明，這些聲明基於當前的期望和假設，因此，受到重大風險和不確定性的影響，這可能導致實際結果與預期結果存在重大差異。這些因素大多數超出了 SeaStar Medical 的控制範圍，且難以預測。可能導致實際未來事件與預期結果存在重大差異的因素包括但不限於：(i) SeaStar Medical 可能無法獲得其 SCD 產品候選者的監管批准的風險；(ii) SeaStar Medical 可能無法籌集足夠資金以資助其運營，包括當前或未來的臨牀試驗的風險；(iii) SeaStar Medical 及其當前和未來的合作伙伴無法成功開發和商業化其產品或服務，或在此過程中經歷重大延遲，包括未能獲得適用的聯邦和州監管機構對其產品的批准的風險；(iv) SeaStar Medical 可能永遠無法實現或維持盈利的風險；(v) SeaStar Medical 可能無法以可接受的條款獲得額外融資的風險；(vi) 第三方供應商和製造商無法完全及時履行其義務的風險；(vii) 與 SeaStar Medical 的產品和服務相關的產品責任或監管訴訟或程序的風險；(viii) SeaStar Medical 無法確保或保護其知識產權的風險；以及 (ix) SeaStar Medical 在其 10-K 表格的年度報告中不時指出的其他風險和不確定性，包括 “風險因素” 部分及 SeaStar Medical 向 SEC 提交的其他文件中的內容。上述因素清單並不詳盡。前瞻性聲明僅在作出之日有效。讀者被提醒不要過度依賴前瞻性聲明，SeaStar Medical 不承擔任何義務，也不打算更新或修訂這些前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
<p>聯繫方式：</p>
<p>IR@SEASTARMED.COM</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png"/></p>

<p>SeaStar Medical 宣佈將於 2026 年 1 月 5 日實施 1 比 10 的反向股票拆分，以重新符合納斯達克 1.00 美元的最低報價要求。股票將以新的 CUSIP 編號 81256L302 進行交易，但保留股票代碼 "ICU"。股東在 2025 年 12 月 18 日的特別會議上批准了此次拆分。零碎股份將被四捨五入為整股。此次拆分將按比例影響股票期權和認股權證</p>

<p>DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company’s 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company’s common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Market (Nasdaq) effective with the open of the market on January 5, 2026. SeaStar Medical’s stock will continue to trade under the ticker symbol “ICU.”</p>
<div class="lb-trans"><p>丹佛，2025 年 12 月 23 日（GLOBE NEWSWIRE）-- SeaStar Medical Holding Corporation（納斯達克：ICU）是一家商業階段的醫療保健公司，專注於改變面臨器官衰竭和潛在生命危險的重症患者的治療，今天宣佈公司將進行 1 比 10 的反向股票拆分（Reverse Split），該拆分將於 2026 年 1 月 5 日東部時間凌晨 12:01 生效。公司的普通股將在 2026 年 1 月 5 日市場開盤時開始以拆分後調整的基礎在納斯達克資本市場（Nasdaq）交易。SeaStar Medical 的股票將繼續以 “ICU” 的股票代碼交易。</p>
</div><p>Authorization for the Reverse Split was approved by the Company’s stockholders at SeaStar Medical’s 2025 Special Meeting of Stockholders held on December 18, 2025. The objective of the Reverse Split is to increase the market price for the Company’s common stock to, among things, enable the Company to regain compliance with the $1.00 minimum bid price requirement under applicable Nasdaq Listing Rules. The Company's common stock will trade under a new CUSIP number – 81256L302.</p>
<div class="lb-trans"><p>反向拆分的授權已於 2025 年 12 月 18 日在 SeaStar Medical 的 2025 年特別股東會議上獲得公司股東的批准。反向拆分的目的是提高公司普通股的市場價格，以便使公司重新符合納斯達克上市規則下的 1.00 美元最低出價價格要求。公司的普通股將以新的 CUSIP 號碼進行交易 – 81256L302。</p>
</div><p>As a result of the Reverse Split, each 10 pre-split shares of common stock outstanding will automatically combine and convert to 1 issued and outstanding share of common stock. Stockholders of record who otherwise would be entitled to receive fractional shares will receive one whole share of common stock in lieu of such fractional share. The Reverse Split reduces the number of shares of common stock issuable upon the exercise or vesting of its outstanding stock options and certain warrants in proportion to the ratio of the Reverse Split and causes a proportionate increase in the exercise prices of such stock options and warrants.</p>
<div class="lb-trans"><p>由於反向拆分，每 10 股拆分前的普通股將自動合併並轉換為 1 股已發行和流通的普通股。記錄在冊的股東如果有權獲得部分股份，將收到一整股普通股以替代該部分股份。反向拆分減少了因行使或歸屬其未發行股票期權和某些認股權證而可發行的普通股數量，按反向拆分的比例調整，並導致這些股票期權和認股權證的行使價格按比例上升。</p>
</div><p>Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Continental Stock Transfer and Trust Company. Continental Stock Transfer and Trust Company can be reached at 800-509-8856. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers’ particular processes.</p>
<div class="lb-trans"><p>記錄在冊的股東將在反向股票拆分後收到來自公司的過户代理人——大陸股票轉讓和信託公司（Continental Stock Transfer and Trust Company）關於其股份所有權的信息。大陸股票轉讓和信託公司可通過 800-509-8856 聯繫。通過銀行、經紀人或其他代理持有股份的股東，其持倉將自動調整以反映反向拆分，無需在反向拆分中採取進一步行動，具體取決於經紀人的特定流程。</p>
</div><p>For additional information regarding the Reverse Split, please refer to SeaStar Medical’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 18, 2025.</p>
<div class="lb-trans"><p>有關反向拆分的更多信息，請參閲 SeaStar Medical 於 2025 年 12 月 18 日向證券交易委員會提交的 8-K 表格當前報告。</p>
</div><p>About SeaStar Medical</p>
<div class="lb-trans"><p>關於 SeaStar Medical</p>
</div><p>SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.</p>
<div class="lb-trans"><p>SeaStar Medical 是一家商業階段的醫療保健公司，專注於改變面臨器官衰竭和潛在生命危險的重症患者的治療。QUELIMMUNE（SCD-PED）療法是 SeaStar Medical 基於其專利選擇性細胞治療設備（SCD）技術的首個商業產品。QUELIMMUNE（SCD-PED）療法於 2024 年獲得美國食品藥品監督管理局（FDA）的批准。它是 FDA 批准的唯一針對因膿毒症或膿毒症狀態導致的危及生命的急性腎損傷（AKI）在重症兒科患者中的超罕見病症的產品。SeaStar Medical 的選擇性細胞治療設備（SCD）療法已獲得 FDA 對六種治療適應症的突破性設備認定，使其在批准和商業推出時具有更快速的審批路徑和更有利的報銷動態。該公司目前正在進行針對需要持續腎臟替代治療（CRRT）的急性腎損傷（AKI）成年患者的 SCD 療法的 NEUTRALIZE-AKI 關鍵試驗，這是一種沒有有效治療方案的危及生命的疾病，每年影響美國超過 200,000 名成年人。</p>
</div><p>For more information visit www.seastarmedical.com or visit us on LinkedIn or X.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.seastarmedical.com 或在 LinkedIn 或 X 上關注我們。</p>
</div><p>Forward-Looking Statements</p>
<div class="lb-trans"><p>前瞻性聲明</p>
</div><p>This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the proposed reverse stock split and the ability of SeaStar Medical to regain compliance with Nasdaq listing rules. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1955 年《私人證券訴訟改革法》“安全港” 條款的某些前瞻性聲明。這些前瞻性聲明包括但不限於，SeaStar Medical 對擬議的反向股票拆分的預期以及 SeaStar Medical 重新符合納斯達克上市規則的能力。諸如 “相信”、“項目”、“期望”、“預期”、“估計”、“打算”、“戰略”、“未來”、“機會”、“計劃”、“可能”、“應該”、“將”、“會”、“將會”、“將繼續”、“可能導致” 等類似表達旨在識別這些前瞻性聲明。前瞻性聲明是關於未來事件的預測、展望和其他聲明，這些聲明基於當前的期望和假設，因此，受到重大風險和不確定性的影響，這可能導致實際結果與預期結果存在重大差異。這些因素大多數超出了 SeaStar Medical 的控制範圍，且難以預測。可能導致實際未來事件與預期結果存在重大差異的因素包括但不限於：(i) SeaStar Medical 可能無法獲得其 SCD 產品候選者的監管批准的風險；(ii) SeaStar Medical 可能無法籌集足夠資金以資助其運營，包括當前或未來的臨牀試驗的風險；(iii) SeaStar Medical 及其當前和未來的合作伙伴無法成功開發和商業化其產品或服務，或在此過程中經歷重大延遲，包括未能獲得適用的聯邦和州監管機構對其產品的批准的風險；(iv) SeaStar Medical 可能永遠無法實現或維持盈利的風險；(v) SeaStar Medical 可能無法以可接受的條款獲得額外融資的風險；(vi) 第三方供應商和製造商無法完全及時履行其義務的風險；(vii) 與 SeaStar Medical 的產品和服務相關的產品責任或監管訴訟或程序的風險；(viii) SeaStar Medical 無法確保或保護其知識產權的風險；以及 (ix) SeaStar Medical 在其 10-K 表格的年度報告中不時指出的其他風險和不確定性，包括 “風險因素” 部分及 SeaStar Medical 向 SEC 提交的其他文件中的內容。上述因素清單並不詳盡。前瞻性聲明僅在作出之日有效。讀者被提醒不要過度依賴前瞻性聲明，SeaStar Medical 不承擔任何義務，也不打算更新或修訂這些前瞻性聲明，無論是由於新信息、未來事件還是其他原因。</p>
</div><p>Contact:</p>
<div class="lb-trans"><p>聯繫方式：</p>
</div><p>IR@SEASTARMED.COM</p>
<div class="lb-trans"><p>IR@SEASTARMED.COM</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qYzROQ00zTXpNMU1qazNJekl5T1RrMU16TT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjc4NCM3MzM1Mjk3IzIyOTk1MzM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png" alt="" original-src="https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png"/></p>

SeaStar Medical 宣佈進行 1 比 10 的反向拆股 | ICU 股票新聞